Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
The inhibition of two immune checkpoints, LAG-3 and PD-1, provided a greater benefit with regard to progression-free survival than inhibition of PD-1 alone in patients with prev...